I agree. If abbv/enta combo turns out to be very profitable (which also depends on the longevity of the HCV mkt and the success of enta next gen HCV pipeline), it is a matter of IRR calculation for abbv to decide to buy enta outright or keep sending a stream of royalties to enta for so many yrs.
Market Data 
Markets 
AI
